Use of dendritic cells (DCs) expressing interleukin 12 (IL-12)

Details Use of dendritic cells (DCs) expressing interleukin 12 (IL-12) Use of dendritic cells (DCs) expressing interleukin 12 (IL-12)

2011-01-11

2011-01-11

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C435S325000, C435S372000, C435S372300, C435S375000, C435S377000, C424S085100

Reexamination Certificate

active

07867488

ABSTRACT:
The present invention discloses the use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific pathogen or a specific tumor and, due to the treatment with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), release IL-12, for the preparation of a medicament for treating a patient having an infection with said specific pathogen or for treating a patient having said specific tumor.

REFERENCES:
patent: 6479254 (2002-11-01), Ebner et al.
patent: 2005/0059151 (2005-03-01), Bosch
Felzmann et al., Cancer Letters, Jul. 26, 2001, vol. 168:145-154.
Asavaroengchai et al., PNAS, Jan. 22, 2002, vol. 99:931-936.
Rieser, Urol. Int., 1999, vol. 63(3):151-159.
Felzmann et al., Cancer Letters, 2000, vol. 161:241-250.
Fong et al., Annu. Rev. Immunol., 2000, 18:245-273.
Lopointe et al., Eur. J. Immunol., 2000, 30:3291-3298.
Felzmann, Thomas et al., “Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes” Cancer Letters, vol. 168, No. 2, Jul. 26, 2001, pp. 145-154.
Rieser, Claudia et al., “Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastic renal cell carcinoma” Urolgia Internationalis, vol. 63, No. 3, 1999, pp. 151-159.
Felzmann, Thomas et al., “Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycation and liposomes” Cancer Letters, Nol. 161, No. 2, Dec. 2000, pp. 241-250.
Cella, M. et al., “Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation”, Journal of Experimental Medicine, vol. 184, No. 2, 1996, pp. 747-752.
Banchereau, J. et al., “Dendritic cells and the control of immunity” Nature, vol. 392, Vo. 6673, Mar. 19, 1998, pp. 245-252.
Gitlitz, B.J. et al., “Dendritic cell-based immunotherapy of renal cell carcinoma”, Current Urology Reports, vol. 2, No. 1, Feb. 2001, pp. 46-52.
Czerniecki, Brian J. et al., “Targeting HER-2
eu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion”, Cancer Res., Feb. 15, 2007, vol. 67, No. 4, pp. 1842-1852.
Davis, Daniel M., “Mechanisms and functions for the duration of intercellular contacts made by lymphocytes”, Nature Reviews Immunology, Aug. 2009, vol. 9, pp. 543-555.
Dohnal, A. M. et al., “Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer”, Cytotherapy, 2007, vol. 9, No. 8, pp. 755-770.
Dohnal, A. M. et al., “Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines”, J. Cell. Mol. Med., 2009, vol. 13, No. 1, pp. 125-135.
Dohnal, A. M. et al., “ CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression”, J. Cell. Mol. Med., 2009, vol. 13. No. 8, pp. 1741-1750.
Felzmann, Thomas et al., “Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses”, Cancer Immunol. Immunother., 2005, vol. 54, pp. 769-780.
Huettner, Katharaina Gabriela et al., “Generation of potent anti-tumor immunity in mice by interleukin-12 secreting dendritic cells”, Cancer Immunol Immunother, 2005, Vo. 54, pp. 67-77.
Kalinski, Pawel et al., “Final maturation of dendritic cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells”, The Journal of Immunology, 1999, vol. 162, pp. 3231-3236.
Langenkamp, Anja et al., “Kinetics of dendritic cell activation: impact on primin of TH1, TH2 and nonpolarized T cells”, Nature Immunology, Oct. 2000, vol. 1, No. 4, pp. 311-316.
Luo, Jun-Li et al., “IKK/NF-κB signaling: balancing life and death—a new approach to cancer therapy”, The Journal of Clinical Investigation, Oct. 2005, vol. 115, No. 10, pp. 2625-2632.
Steinman, Ralph M. et al., “Taking dendritic cells into medicine”, Nature, Sep. 27, 2007, vol. 449, pp. 419-426.
Suffredini, Anthony F. et al., “Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot ofEscherichia coliO:113 endotoxi”, The Journal of Infectious Diseases, 1999, vol. 179, pp. 1278-1282.

Affiliated with

Also associated with

Rating

Use of dendritic cells (DCs) expressing interleukin 12 (IL-12) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of dendritic cells (DCs) expressing interleukin 12 (IL-12), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dendritic cells (DCs) expressing interleukin 12 (IL-12) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2663854